Microdosing psilocybin mushrooms for depression involves taking a very small, sub-perceptual dose, typically 0.1 to 0.5 grams of dried mushroom material, on a structured schedule over several weeks. The practice has generated enormous interest, but the honest picture is more complicated than social media suggests: rigorous clinical trials have not yet confirmed that microdosing works better than placebo for depression, even though observational reports and anecdotal accounts are overwhelmingly positive. Here’s what’s known about how people do it, what the science actually says, and what to watch out for.
Typical Dose Range
A microdose is roughly one-tenth of what would produce a noticeable psychedelic experience. For dried Psilocybe cubensis, the most commonly used species, that translates to 0.1 to 0.5 grams. At the low end (0.1 g), most people feel nothing obvious. At 0.5 g, some people begin to notice subtle shifts in mood or perception, which means they’ve likely crossed the “sub-perceptual” threshold. The goal is to stay below that line.
Potency varies significantly between mushroom species, individual batches, and even different parts of the same mushroom. Caps and stems can contain different concentrations of psilocybin. This inconsistency is one of the biggest practical challenges. Most experienced microdosers address it by grinding an entire batch of dried mushrooms into a fine powder, mixing thoroughly, and then weighing individual doses on a milligram-precision scale. The powder is often packed into small gel capsules for consistency. Without this homogenization step, one 0.2 g dose could feel noticeably different from the next.
Common Dosing Schedules
Two protocols dominate the microdosing community. The Fadiman protocol, named after psychologist James Fadiman, follows a simple pattern: one dose day, two days off, repeat. So you’d dose on day one, rest on days two and three, dose again on day four, and continue this cycle for several weeks before taking a longer break of one to two weeks. The rest days are considered important both for preventing tolerance and for observing any lingering effects on off days.
The Stamets protocol, associated with mycologist Paul Stamets, uses a different rhythm: four consecutive days on, three days off. Stamets also recommends combining the psilocybin with lion’s mane mushroom and niacin, a combination he calls “stacking,” though clinical evidence for the added benefit of this combination is limited.
In practice, many people eventually abandon strict schedules and dose according to how they feel, sometimes described as “intuitive microdosing.” Survey data from microdosing communities confirms this is common. People adjust both the amount and frequency based on personal response, which is part of why studying this practice in controlled settings is so difficult.
What Happens in the Brain
When you ingest psilocybin, your body quickly converts it into psilocin, the compound that actually affects your brain. Psilocin binds to serotonin receptors, particularly one type that plays a central role in mood regulation. This binding appears to trigger two things relevant to depression. First, it promotes the growth of new connections between brain cells, a process called neuroplasticity. Animal research shows that psilocybin increases the density of these synaptic connections, and this structural change persists after the drug itself has cleared the system. Second, it temporarily reduces the density of serotonin receptors on cell surfaces, which may help “reset” signaling patterns that have become dysfunctional in depression.
These mechanisms have been demonstrated most clearly at full psychedelic doses, not microdoses. Whether the tiny amounts used in microdosing trigger the same neuroplastic changes remains an open and important question.
What the Clinical Evidence Shows
This is the part that trips up most articles on the topic. Anecdotal reports and observational surveys consistently show that people who microdose report improvements in mood, creativity, and overall well-being. But when researchers run double-blind, placebo-controlled trials, the picture changes. Studies have found that people receiving placebo capsules report similar benefits to those receiving actual psilocybin, as long as they don’t know which group they’re in. Some studies found no statistically significant difference between microdosing and placebo groups.
These results don’t necessarily mean microdosing is useless. The existing trials have been small and have faced methodological challenges, particularly around maintaining blinding (participants often guess correctly whether they got the real thing). A phase II clinical trial specifically designed to test microdosed psilocybin against placebo for major depressive disorder is now underway, and its results will provide much stronger evidence one way or the other. For now, the honest summary is: the placebo effect is powerful, and we can’t yet separate it from any genuine pharmacological benefit of microdosing.
Full-dose psilocybin therapy, by contrast, has shown much stronger clinical results for depression in multiple rigorous trials. The distinction matters. People sometimes assume microdosing carries the same evidence base as the psilocybin therapy making headlines, but these are fundamentally different approaches.
The Afterglow Period
Even at full doses, psilocybin’s mood-lifting effects extend well beyond the hours when the drug is active in your system. This residual period, called the “afterglow,” typically lasts days to weeks, gradually fading over two to four weeks. Microdosers often report a similar phenomenon on a smaller scale: the day after a microdose sometimes feels better than the dose day itself. This may partly explain why protocols build in rest days, as the off days may carry residual benefit while allowing tolerance to reset.
Interactions With Antidepressants
If you’re currently taking an SSRI or SNRI antidepressant, this is critical information. These medications significantly blunt psilocybin’s effects. In a large survey-based study of over 600 reports, people taking SSRIs had a 47% probability of experiencing weaker-than-expected effects from psilocybin mushrooms. For SNRIs, that number rose to 55%. Bupropion, which works through a different mechanism, showed less interference at 29%.
Perhaps more striking: this dampening effect persists long after stopping the antidepressant. The probability of reduced psilocybin effects didn’t drop to baseline until three to six months after discontinuing an SSRI or SNRI. This means that simply skipping your antidepressant for a few days or weeks before microdosing is unlikely to make the psilocybin work normally, and abruptly stopping antidepressants carries its own serious risks including withdrawal symptoms and depressive rebound.
Potential Long-Term Safety Concerns
One underreported risk involves the heart. Psilocin activates a serotonin receptor subtype that, when stimulated repeatedly over long periods, has been linked to changes in heart valve tissue. This is the same mechanism that caused the weight-loss drug fenfluramine to be pulled from the market. No one has documented heart valve problems from psilocybin microdosing in humans, but no one has studied it either. The concern is theoretical but biologically plausible, and it’s especially relevant because microdosing involves repeated, sustained exposure over weeks or months, exactly the pattern most likely to cause problems through this pathway.
Legal Status
Psilocybin remains a Schedule I controlled substance under U.S. federal law, making possession illegal regardless of the amount or intended use. A handful of jurisdictions have moved to deprioritize enforcement or create limited legal access. Several California cities, including Oakland, Santa Cruz, Berkeley, and San Francisco, have made personal possession of entheogenic plants the lowest law enforcement priority. Ann Arbor, Detroit, and Hazel Park in Michigan have done the same. Colorado has gone further, legalizing regulated therapeutic access. Texas has funded pilot programs for psilocybin-assisted therapy for veterans, retired first responders, and healthcare workers, though these operate under strict clinical supervision and federal oversight.
Deprioritization is not the same as legalization. In most of the U.S., purchasing, possessing, or cultivating psilocybin mushrooms carries real legal risk.
Practical Considerations
People who microdose generally follow a few consistent practices. Starting at the lowest dose (around 0.1 g of dried, ground material) and increasing gradually helps identify your sub-perceptual threshold. Taking the dose in the morning avoids any potential sleep disruption. Keeping a daily journal to track mood, sleep, anxiety, and energy gives you actual data rather than relying on general impressions, which are highly susceptible to expectation effects.
Storage matters for consistency. Dried, ground mushroom material should be kept in an airtight container away from light and moisture. Psilocybin degrades over time, especially when exposed to heat or UV light, so older material may be less potent. If you’ve prepared capsules from a single batch, they should remain relatively consistent as long as the powder was mixed thoroughly before filling.
Given how strong the placebo response has been in microdosing research, some self-experimenters have adopted a simple blinding technique: preparing identical capsules with and without psilocybin, randomizing which they take on dose days, and only checking which was which after a few weeks. This won’t meet scientific standards, but it can help you gauge whether what you’re feeling is connected to the compound itself or to the ritual and expectation surrounding it.